Mark Yarchoan: Recent Advances in Therapeutic Cancer Vaccines
Mark Yarchoan, Associate Professor at Johns Hopkins Hospital, shared a recent article by him and colleagues on X:
“Our new review is out today in Nature Reviews Cancer—on why therapeutic cancer vaccines are finally gaining traction after decades of setbacks.
Earlier approaches—vaccines targeting overexpressed self-antigens as monotherapy in late-line disease—failed due to immune tolerance, weak immunogenicity, and exhaustion. Clinically, it was akin to giving COVID vaccine to someone in the ICU with severe COVID
The new paradigm focuses on neoantigen vaccines in early-stage cancers, often in the adjuvant setting and combined with ICIs. Early clinical data in melanoma, PDAC, and more are promising—and point to therapeutic potential
Many big questions remain: ideal platforms, personalized vs. off-the-shelf approaches, optimal combinations, and more. The next few years are critical, with multiple pivotal trials expected to report soon.
Decades of failure have informed today’s progress. Therapeutic vaccines may finally emerge as a core component of cancer care.”
Title: Recent advances in therapeutic cancer vaccines
Authors: Neeha Zaidi, Elizabeth Jaffee, Mark Yarchoan
Read The Full Article at Nature Reviews Cancer.
More posts featuring Cancer Vaccines.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023